Body mass index is an independent risk factor for the development of endometrial polyps in patients undergoing in vitro fertilization
Received 15 September 2007; received in revised form 2 January 2008; accepted 2 January 2008. published online 05 March 2008.
Objective
To determine the subgroup of patients in whom office hysteroscopy should be routinely performed before an in vitro fertilization (IVF) program.
Design
Retrospective cohort analysis.
Setting
Tertiary education and research hospital.
Patient(s)
Two hundred twenty-three patients who underwent a uterine evaluation by office hysteroscopy before the IVF and embryo transfer cycle.
Intervention(s)
The office hysteroscopy was performed in the follicular phase of the menstrual cycle before the IVF cycle.
Main Outcome Measure(s)
The office findings: number of polyps, number of multiple polyps, and polyp size.
Result(s)
Patients with polycystic ovary syndrome (PCOS) had a higher number of endometrial polyps, but the difference was not statistically significant (28.9% vs. 18.3%). When comparing the patients according to BMI, patients with BMI ≥30 had a statistically significantly higher number of endometrial polyps versus BMI <30 (52% vs. 15%). On the other hand, obesity was positively correlated with the occurrence of polyps, size of the polyps, and occurrence of multiple number of polyps in the correlation analysis. In addition, logistic regression analysis using age, obesity, duration of infertility, and estradiol levels revealed that obesity was an independent prognostic factor for the development of endometrial polyps.
Conclusion(s)
Office hysteroscopy should be performed in patients with BMI ≥30 because obesity may act as an initiator for the pathogenesis of endometrial polyps.
aObstetrics and Gynecology, Zekai Tahir Burak Women's Education and Research Hospital, Ankara, Turkey
bObstetrics and Gynecology, Baskent University School of Medicine, Ankara, Turkey
Reprint requests: Gogsen Onalan, M.D., Baskent University School of Medicine, Kubilay Sok no. 36 Maltepe, Ankara, Turkey, 06570 (FAX: +90-312-2323912).
Presented in part at the 63rd Annual Meeting of the American Society for Reproductive Medicine, October 13–17, 2007, Washington, D.C.
ABSTRACT